Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-Health for Zero Infections PrEP monitoring trial
NL-OMON54198Completed
- Sponsor
- Public Health Service of Amsterdam
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Public Health Service of Amsterdam. Primary endpoint: Adherence to PrEP. Started Sep 2021; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON54198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54198.